跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
T-cell therapy
首页
药物
T-cell therapy
T-cell therapy
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
METHODS OF CONDITIONING PATIENTS FOR T CELL THERAPY
EP 3302508 A4
申请人: US HEALTH
优先权: 2015
CN
EP
US
WO
14 件公开
METHODS FOR PREPARING T-CELLS FOR CELL THERAPY
EP 3067415 A1
申请人: IMMUNOVATIVE THERAPIES LTD
优先权: 2004
EP
US
13 件公开
DIAGNOSTIC METHODS FOR T CELL THERAPY
EP 3302507 A4
申请人: US HEALTH
优先权: 2015
CN
EP
US
WO
11 件公开
GENERATING MAMMALIAN T CELL ACTIVATION INDUCIBLE SYNTHETIC PROMOTERS (SYN+PRO) TO IMPROVE T CELL THERAPY
EP 3624814 A4
申请人: SEATTLE CHILDRENS HOSPITAL DBA SEATTLE CHILDRENS RES INST
优先权: 2017
CN
EP
US
WO
10 件公开
COMPOSITIONS AND METHODS FOR ENHANCING ADOPTIVE T CELL THERAPEUTICS
EP 4593850 A4
申请人: UNIV CALIFORNIA
优先权: 2022
CN
EP
US
WO
9 件公开
BCMA-TARGETED CAR-T CELL THERAPY FOR MULTIPLE MYELOMA
EP 4255450 A1
申请人: JANSSEN BIOTECH INC
优先权: 2020
CN
EP
US
WO
8 件公开
EP 4698190 A1
申请人: LEGEND BIOTECH USA INC
优先权: 2023
EP
US
WO
7 件公开
US 20250269024 A1
申请人: LEGEND BIOTECH USA INC
优先权: 2024
US
WO
2 件公开
US 20250339527 A1
申请人: LEGEND BIOTECH USA INC
优先权: 2024
US
WO
2 件公开
CN 118900698 A
申请人: JANSSEN BIOTECH INC
优先权: 2022
CN
TN-MUC1 CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL THERAPY
EP 3947471 A4
申请人: UNIV PENNSYLVANIA
优先权: 2019
CN
EP
US
WO
7 件公开
BCMA-TARGETED CAR-T CELL THERAPY OF MULTIPLE MYELOMA
EP 4055049 A1
申请人: JANSSEN BIOTECH INC
优先权: 2019
CN
EP
US
WO
6 件公开
CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY
EP 4054603 A4
申请人: KITE PHARMA INC
优先权: 2019
CN
EP
US
WO
6 件公开
EP 4106775 A1
申请人: KITE PHARMA INC
优先权: 2020
EP
US
WO
5 件公开
EP 4403224 A3
申请人: KITE PHARMA INC
优先权: 2018
CN
EP
US
WO
4 件公开
EP 4106774 A4
申请人: KITE PHARMA INC
优先权: 2020
EP
US
WO
4 件公开
EP 4337227 A2
申请人: KITE PHARMA INC
优先权: 2021
EP
US
WO
4 件公开
CN 117295507 A
申请人: KITE PHARMA INC
优先权: 2022
CN
METHODS OF PREPARING T CELLS FOR T CELL THERAPY
EP 3702447 A1
申请人: KITE PHARMA INC
优先权: 2015
CN
EP
US
6 件公开
EP 4025688 A1
申请人: ALLOGENE THERAPEUTICS INC
优先权: 2019
CN
EP
US
3 件公开
第 1 / 9 页
上一页
下一页
药物
反馈